PainReform Ltd. (NASDAQ:PRFX) Sees Significant Increase in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 313,070 shares, an increase of 324.9% from the May 14th total of 73,684 shares. Based on an average trading volume of 8,718,443 shares, the days-to-cover ratio is currently 0.0 days. Approximately 54.9% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

PainReform Price Performance

Shares of PRFX traded down $0.07 during midday trading on Thursday, hitting $1.48. The stock had a trading volume of 103,976 shares, compared to its average volume of 1,353,102. PainReform has a 1 year low of $1.28 and a 1 year high of $17.95. The firm has a market cap of $1.29 million, a PE ratio of 0.00 and a beta of 0.98. The stock’s 50 day moving average is $2.01 and its 200 day moving average is $3.07.

PainReform (NASDAQ:PRFX) last announced its earnings results on Thursday, March 26th. The company reported ($1.01) earnings per share for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.